Atara Biotherapeutics (ATRA) AI Stock Analysis

• Market Cap: $101.69M
• Dividend Yield: N/A
• Average Volume (3M): 53.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: 202.41%
• EPS Growth: 98.99%
• Country: US
• Employees: 153
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.19
• Shares Outstanding: 7,023,032
• 10 Day Avg. Volume: 68,313
• 30 Day Avg. Volume: 53,248
• PEG Ratio: 0.01
• Price to Book (P/B): -1.02
• Price to Sales (P/S): 0.77
• P/FCF Ratio: -1.45
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 0.70
• Enterprise Value/Gross Profit: 0.86
• Enterprise Value/Ebitda: 9.17
• 1Y Price Target: $16.50
• Price Target Upside: 14.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 51 Neutral
• Price Target: $14.50 ▲(0.62% Upside)

Atara Biotherapeutics' overall stock score is primarily impacted by its financial instability, with negative equity and cash flow issues being significant concerns. The technical analysis provides some positive momentum, but valuation metrics are weak due to negative earnings. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Innovative Product Pipeline

Atara's focus on innovative T-cell therapies like ATA188 and ATA3219 positions it strongly in the biotech sector, potentially leading to breakthrough treatments for cancer and autoimmune diseases.

High Gross Profit Margin

A high gross profit margin indicates effective cost management and potential for profitability as revenues grow, supporting long-term operational sustainability.

Strategic Partnerships

Strategic partnerships with larger pharmaceutical companies provide crucial funding and resources, enhancing Atara's ability to develop and commercialize its therapies.

Negative Factors

Negative Equity

Negative equity indicates potential solvency issues, posing a risk to financial stability and limiting the company's ability to raise capital or invest in growth initiatives.

Negative Cash Flow

Persistent negative cash flow challenges Atara's ability to fund operations and invest in R&D, potentially impacting long-term growth and sustainability.

Declining Revenue Growth

Declining revenue growth reflects challenges in maintaining sales momentum, which could hinder Atara's ability to scale and achieve profitability in the competitive biotech market.

Atara Biotherapeutics Business Overview & Revenue Model

Company Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

How the Company Makes Money

Atara Biotherapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its therapies. The company may also receive milestone payments based on the achievement of certain development goals and royalties on future sales of approved products. Additionally, Atara may engage in licensing agreements that allow other companies to develop and commercialize its technologies, further contributing to its income streams. Research grants and government funding may also play a role in supporting its operational costs.

Atara Biotherapeutics Financial Statement Overview

Summary

Atara Biotherapeutics faces significant financial challenges. Despite a high gross profit margin, the company struggles with low net profit and negative revenue growth. The balance sheet is unstable with negative equity, and cash flow issues further exacerbate the situation, indicating a need for strategic financial management.

Income Statement

Atara Biotherapeutics shows a mixed performance in its income statement. The company has a positive gross profit margin of 79.32% TTM, indicating efficient cost management relative to revenue. However, the net profit margin is low at 3.39% TTM, and revenue growth is negative at -5.54% TTM, reflecting challenges in maintaining revenue levels. The EBIT and EBITDA margins are modest at 3.85% and 8.13% TTM, respectively, suggesting limited operational profitability.

Balance Sheet

The balance sheet reveals significant financial instability. The company has a negative stockholders' equity, leading to a negative debt-to-equity ratio of -0.44 TTM, which is concerning. The return on equity is also negative, indicating losses relative to shareholder investments. The equity ratio is not directly calculable due to negative equity, highlighting potential solvency issues.

Cash Flow

Cash flow analysis shows a challenging situation with negative operating and free cash flows. The free cash flow growth rate is negative at -4.98% TTM, and the operating cash flow to net income ratio is -4.39 TTM, indicating cash flow issues relative to earnings. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally covering net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	188.67M	128.94M	8.57M	63.57M	20.34M	0.00
Gross Profit	153.28M	107.93M	-313.00K	49.01M	8.96M	-9.87M
EBITDA	14.31M	-75.75M	-266.00M	-213.72M	-331.12M	-296.74M
Net Income	5.79M	-85.40M	-276.13M	-2.28B	-3.40B	-3.07B
Balance Sheet
Total Assets	36.90M	109.10M	165.50M	376.42M	468.13M	588.12M
Cash, Cash Equivalents and Short-Term Investments	22.32M	42.50M	51.73M	242.82M	371.07M	500.66M
Total Debt	15.43M	43.83M	57.87M	71.70M	28.27M	13.04M
Total Liabilities	71.94M	206.38M	264.74M	249.78M	188.51M	125.78M
Stockholders Equity	-35.04M	-97.28M	-99.23M	126.64M	279.61M	462.34M
Cash Flow
Free Cash Flow	-64.01M	-68.96M	-194.20M	-274.62M	-231.10M	-185.27M
Operating Cash Flow	-63.92M	-68.72M	-192.98M	-270.43M	-220.52M	-180.76M
Investing Cash Flow	-1.16M	8.62M	123.87M	202.96M	22.26M	-120.73M
Financing Cash Flow	50.52M	59.28M	2.01M	53.08M	103.94M	427.57M

Atara Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.41
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Positive. The current price of 14.41 is above the 20-day moving average (MA) of 12.90, above the 50-day MA of 12.26, and above the 200-day MA of 9.43, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 68.37 is Neutral, neither overbought nor oversold. The STOCH value of 85.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATRA.

Atara Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATRA	51 Neutral	$101.69M	―	1063.61%	―	202.41%	98.99%
KPTI	50 Neutral	$54.54M	―	41.08%	―	-5.77%	-22.78%
HOWL	48 Neutral	$87.80M	―	-100.55%	―	-100.00%	-22.09%
NRXP	45 Neutral	$79.15M	―	108.28%	―	―	18.51%
LTRN	45 Neutral	$43.41M	―	-88.59%	―	―	-8.47%
XFOR	44 Neutral	$78.12M	0.66	-207.22%	―	5721.31%	-671.01%

Atara Biotherapeutics Corporate Events

Atara Biotherapeutics Reduces Board Size, Appoints New Chair

On September 2, 2025, Atara Biotherapeutics announced a strategic reduction in its Board of Directors from ten to seven members to better align with its current operations and the boards of similar-sized public companies. This decision led to the voluntary resignation of directors Ameet Mallik, Pascal Touchon, and Maria Grazia Roncarolo, M.D., with Gregory A. Ciongoli being appointed as the new Chair of the Board, replacing Pascal Touchon.

Atara Biotherapeutics Resubmits BLA for Tab-cel to FDA

On July 14, 2025, Atara Biotherapeutics announced the resubmission of its Biologics License Application (BLA) for tabelecleucel (tab-cel®) to the U.S. FDA, aimed at treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). This resubmission follows collaborative efforts with Pierre Fabre Laboratories to address manufacturing observations noted in a previous Complete Response Letter. Approval of the BLA could trigger a $40 million milestone payment from Pierre Fabre Laboratories. Atara is also finalizing the transfer of clinical studies and operational activities related to tab-cel to Pierre Fabre Laboratories, while maintaining sponsorship of the BLA. The company projects that its current financial resources will support operations into the first quarter of 2026, contingent on achieving BLA approval.

Atara Biotherapeutics Holds Annual Stockholders Meeting

On June 10, 2025, Atara Biotherapeutics held its annual stockholders meeting, where several key decisions were made. The election of directors resulted in the appointment of three nominees to serve until 2028. Additionally, stockholders approved the executive compensation plan and decided to hold annual advisory votes on this matter. Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.